Entasis Therapeutics Holdings Inc., of Waltham, Mass., disclosed an agreement with in vitro diagnostics firm Biomerieux SA, of Lyon, France, in which Entasis will incorporate Biofire Filmarray instruments and Biofire Filmarray pneumonia panels into its global phase III trial for antibacterial ETX-2514SUL for enrollment optimization. Terms were not disclosed.